Charles River Laboratories has signed a collaboration with Ipsen to use its virtual control group, or VCG, database in a toxicology study, moving a new approach methodology from general promise into a prospective regulated application.
Under the arrangement, Charles River will provide VCG data to support prospective analysis of general toxicology endpoints in Ipsen’s good laboratory practice-compliant study. Charles River said the database and methodology are intended to digitally replace a portion of concurrent control animals in safety studies.
The Study Setup
The source material does not name the Ipsen asset involved, but it does define the use case narrowly: a general toxicology study run under GLP standards. That matters because adoption of alternative methods often stalls at the point where companies have to fit them into established regulatory study designs rather than use them in exploratory research.
Charles River said VCGs may affect study timelines, enhance data quality and meet regulatory expectations tied to the 3Rs: replacement, reduction and refinement of animal use in research. The company also said the platform draws on historical data plus toxicology and regulatory expertise.
By Charles River’s own estimate, the VCG platform can reduce the need for animals in drug safety studies by up to 12%. The company also argues that the approach can improve statistical power for detecting rare spontaneous findings and provide more consistent interpretation through large historical datasets.
Why This Matters
For Ipsen, which is focused on oncology, rare disease and neuroscience, the collaboration is less about a headline pipeline event than a development operations decision. If VCGs prove workable in a prospective GLP study, they offer a route to make preclinical safety packages somewhat leaner without asking regulators to accept a fully novel evidence model.
For Charles River, the partnership is a commercial validation step for a service built around new approach methodologies. The more immediate signal is not that animal studies are disappearing, but that contract research organizations are trying to insert data-based substitutions into the parts of preclinical development where sponsors can still stay within existing compliance structures.
Charles River has been building that position for some time. In October 2025, the company announced a scientific advisory board to guide its NAM strategy and put former FDA official Namandjé Bumpus at the helm. The broader policy environment has also become more supportive, with agencies including the National Institutes of Health and the FDA pushing NAMs in academic research and clinical drug studies.
